Department of Basic Veterinary Science, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
College of Animal Science, Yili Vocational and Technical College, Yili 835000, Xinjiang, China.
Poult Sci. 2023 Aug;102(8):102761. doi: 10.1016/j.psj.2023.102761. Epub 2023 Apr 27.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) commonly used in an extra-label manner in commercial laying hens for the treatment of foot lesions, which are a common issue in this species. The present study aimed to determine the depletion profiles of meloxicam in eggs with multiple oral administration under 2 different dosing regimens and to further recommend reasonable withdrawal intervals (WDIs). Meloxicam (1 mg/kg) was administered orally to laying hens under 2 dosing schedules: 10 doses at 24-h intervals and 15 doses at 12-h intervals. Eggs were collected daily after the first dosing, and meloxicam concentrations in both yolk and white were determined by a high-performance liquid chromatography (HPLC) method. The weight ratio of white to yolk in the whole egg was 1.54 (the mean of 20 eggs with repeated tests), and this value combined with the meloxicam concentrations in white and yolk were used to calculate the drug concentrations in whole eggs. Meloxicam was quickly eliminated from egg white, and its concentrations could only be quantified at 2 time points during the elimination phase. The elimination half-lives in yolk and whole egg were 3.07 ± 1.00 and 2.98 ± 0.88 d, respectively, after 10 repeated doses. And the corresponding elimination half-lives were 2.30 ± 0.83 and 2.18 ± 0.67 d, respectively, after repeated 15 doses. Considering the time when meloxicam was not detectable in eggs with the time of ovum development and maturation, a withdrawal interval (WDI) was suggested as 17 d for both dosing schedules. The current results enriched the study on the residue of meloxicam in domestic Jing Hong laying hens and provided WDIs to help ensure animal-derived food safety.
美洛昔康是一种非甾体抗炎药(NSAID),常被超说明书用于商业产蛋鸡以治疗足部病变,这在该物种中很常见。本研究旨在确定在两种不同给药方案下多次口服给药时美洛昔康在鸡蛋中的消耗情况,并进一步推荐合理的停药期(WDI)。以两种给药方案对产蛋鸡进行美洛昔康(1mg/kg)口服给药:24 小时间隔给药 10 次和 12 小时间隔给药 15 次。首次给药后每天收集鸡蛋,通过高效液相色谱(HPLC)法测定蛋黄和蛋清中美洛昔康的浓度。全蛋中蛋清与蛋黄的重量比为 1.54(20 个重复测试鸡蛋的平均值),该值与蛋清和蛋黄中的美洛昔康浓度结合使用,计算出全蛋中的药物浓度。美洛昔康从蛋清中迅速消除,在消除阶段只能在 2 个时间点定量检测到其浓度。重复 10 次给药后,蛋黄和全蛋中的消除半衰期分别为 3.07±1.00 和 2.98±0.88d;重复 15 次给药后,相应的消除半衰期分别为 2.30±0.83 和 2.18±0.67d。考虑到鸡蛋中不再检出美洛昔康的时间与卵的发育和成熟时间,建议两种给药方案的停药期(WDI)均为 17d。本研究丰富了国内京红产蛋鸡中美洛昔康残留的研究,为保障动物源性食品安全提供了停药期。